Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma
In managing HD-MTX therapy for PCNSL patients, it is essential to consider pharmacokinetic factors such as eGFR, BUN, ALT, TP, and genetic polymorphisms. The PPK models developed will aid in optimizing and personalizing HD-MTX treatment for PCNSL patients.
Authors
- Shenghui Mei (ORCID: https://orcid.org/0000-0003-1385-4315)
- Yong He (ORCID: https://orcid.org/0000-0002-9404-798X)
- Qian Lü (ORCID: https://orcid.org/0000-0003-2611-3284)
- Shifeng Wei (ORCID: https://orcid.org/0009-0009-7766-9929)
- Sitian Zhang
- Dan Wang (ORCID: https://orcid.org/0000-0001-5007-5703)
- Zhilin Yang
- Zhigang Zhao (ORCID: https://orcid.org/0000-0003-0281-2259)
- Dongjie Zhang (ORCID: https://orcid.org/0000-0003-3536-8422)
- Lili Guan (ORCID: https://orcid.org/0000-0002-2416-8428)
- Jiayi Mo
Institutions
- IE University (ES)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.3389/fphar.2025.1578033
- Citations
- 2
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Capital Medical University
- Beijing Municipal Administration of Hospitals
- National Key Research and Development Program of China